Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Alembic Pharmaceuticals Ltd.
Source DateBoard Meeting DateDetails
18-Oct-2024 07-Nov-2024 Quarterly Results
25-Jul-2024 08-Aug-2024 Quarterly Results
18-Apr-2024 09-May-2024 Audited Results & Final Dividend
18-Jan-2024 05-Feb-2024 Quarterly Results
16-Oct-2023 07-Nov-2023 Quarterly Results
21-Jul-2023 04-Aug-2023 Quarterly Results
24-Apr-2023 05-May-2023 Final Dividend & Audited Results
17-Jan-2023 01-Feb-2023 Quarterly Results
31-Oct-2022 11-Nov-2022 Quarterly Results
20-Jul-2022 04-Aug-2022 Quarterly Results & Interim Dividend
20-Apr-2022 02-May-2022 Audited Results & Dividend
28-Jan-2022 10-Feb-2022 Quarterly Results
29-Oct-2021 10-Nov-2021 Quarterly Results
15-Jul-2021 26-Jul-2021 Quarterly Results
20-Apr-2021 04-May-2021 Dividend & Audited Results
07-Jan-2021 19-Jan-2021 Quarterly Results
09-Oct-2020 22-Oct-2020 Quarterly Results
03-Aug-2020 06-Aug-2020 ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2020 ,inter alia, to consider and approve In terms of Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the ?SEBI LODR Regulations?), we wish to inform you that a meeting of the Fund Raising Committee of the board of the directors of the Company is scheduled to be held on 6th August, 2020 inter alia to consider and approve the issue price, including a discount, if any, thereto as permitted under the SEBI ICDR Regulations, for the Equity Shares to be allotted to qualified institutional buyers, pursuant to the Issue. We request you to take the above on record and the same be treated as compliance under the applicable provisions of the SEBI LODR Regulations.
24-Jul-2020 27-Jul-2020 Inter alia to consider fund raising by way of a qualified institutions placement.
17-Jul-2020 22-Jul-2020 Inter alia to consider fund raising by way of a qualified institutions placement.
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.